ACTG Announces Launch Of ACTIV-2d, A Global Phase 3 Trial of The Novel Investigational COVID-19 Oral Antiviral Agent S‑217622

Media Type
Article
Publish or Event Date
Research Institution
ACTG
Short Title
ACTG Announces Launch Of ACTIV-2d, A Global Phase 3 Trial of The Novel Investigational COVID-19 Oral Antiviral Agent S‑217622